0
0
Read Time:28 Second
On Tuesday, the European Commission granted authorization for GSK’s HIV-focused unit, ViiV Healthcare, to market cabotegravir in both long-acting injectable and tablet forms, announced the British drugmaker.
According to the company, cabotegravir is recommended alongside safer sex practices for pre-exposure prophylaxis (PrEP) in order to mitigate the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilograms.
Currently marketed under the brand name Apretude, this medication is already approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana, and Brazil.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
